A Phase 1, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Patients with Relapsed/Refractory Multiple Myeloma

Sponsor: Novella Clinical, Inc

Location(s): United States


The purpose of this research study is to determine the most effective dose and side effects of CB-5083 given to patients with multiple myeloma whose disease has not responded to (gotten better with) previous types of treatment or responded at first but then relapsed (progressed or got worse). The study will collect information about side effects from taking CB-5083, what the highest dose (amount) is that can be taken without serious or hard to treat side effects, and whether CB-5083 is useful in treating patients with multiple myeloma.